CAS: 711-79-5; 1-(1-Hydroxynaphthalen-2-yl)Ethan-1-One

相似化合物

17056-93-8 574-19-6 574-96-9

上下游产品

malonic acid α-naphthol 1-naphthyl acetate propionyl chloride 1-[1-(4-nitro-benzoyloxy)-[2]naphthyl]-ethanone t-(3-hydroxy-4-methoxy-phenyl)-3-(1-hydroxy-naphthyl-(2))-propen-(1)-one-(3)1t-(3-hydroxy-4-methoxy-phenyl)-3-(1-hydroxy-naphthyl-(2))-propen-(1)-one-(3) 1-(1-ethoxy-[2]naphthyl)-ethanone t-(4-benzyloxy-phenyl)-1-(1-hydroxy-[2]naphthyl)-propenone3t-(4-benzyloxy-phenyl)-1-(1-hydroxy-[2]naphthyl)-propenone

📜在 Palladium(II) Trifluoroacetate,Copper Diacetate体系中,用 1,2-二氯乙烷 作为反应溶剂,化学反应 6.0H,以64%的收率获得产物2-乙酰基-1-萘酚
参考文献:Pd-Catalyzed Sequential C-c Bond Formation And Cleavage: Evidence For An Unexpected Generation Of Arylpalladium(II) Species
标题:Pd-Catalyzed Sequential C-c Bond Formation And Cleavage: Evidence For An Unexpected Generation Of Arylpalladium(II) Species
摘要:A Pd(II)-Catalyzed Reaction Engaging Alkenyl Beta-Keto Esters Is Reported That Leads To The Formation Of 1-Naphthols And An Unexpected Generation Of Arylpalladium-(II) Species. Interception Of The In Situ Generated Arylpalladium(II) Species In A Mizoroki-Heck Reaction,Together With Additional Mechanistic Studies,Provided Strong Evidence In Support Of The First Aromatization-Driven Beta-Carbon Elimination Process. A Single Pd Catalyst Served To Promote A Series Of Both C-C Bond Forming And Cleavage Events In An Unprecedented Manner.
DOI:10.1021/ja304616Q

专利信息

专利号:US-7919505-B2
优先权日:2006-07-11
标题 :Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
发明人：TING PAULINE C; LEE JOE F; FENG KUNG-I; REEDER MICHAEL R; TRZASKA SCOTT T; ZHU MAN; MAO CHEN; FILIPOV DIMITAR L; ZARKADAS DIMITRIOS N
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the formula n nTo methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

专利号:EP-1300403-A1
优先权日:2001-10-02
标 题 :Process for the manufacture of hypoxyxylerone derivatives
发明人：GIMBERT YVES; CHEVENIER EMMANUEL; GREEN ANDREW E; MASSARDIER CHRISTINE; PIETTRE ARNAUD
权利人:AVENTIS PHARMA SA
摘要:The present invention relates to the total synthesis ofnhypoxyxylerone derivatives (formula I) and their biologicalnactivities. n R1-R5 are as described in the description.

专利号:US-7638554-B2
优先权日:2002-04-18
标题 :Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
发明人：WALEH NAHID; ZAVERI NURULAIN T
权利人:STANFORD RES INST INT
摘要:Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) n nwherein R 1 through R 3 and R 5 through R 11 are defined herein, and α, β and γ are optional bonds, providing that when α is absent, β is present, and when β is absent, α is present. When α is present, preferred R 4 moieties are selected from O, S, NH and CH 2 , and when α is absent, preferred R 4 groups are selected from OH, SH, NH 2 and CH 3 . When γ is present, the preferred R 5 substituent is O, while when γ is absent, the preferred R 5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

专利号:US-7329687-B2
优先权日:2002-04-18
标 题:Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents
发明人：ZAVERI NURULAIN; CHAO WAN-RU
权利人:STANFORD RES INST INT
摘要:Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) n nwherein R 1 through R 3 and R 5 through R 11 are defined herein, and α, β, and γ are optional bonds, providing that when α is absent, β is present, and when β is absent, α is present. When α is present, preferred R 4 moieties are selected from O, S, NH and CH 2 , and when α is absent, preferred R 4 groups are selected from OH, SH, NH 2 and CH 3 . When γ is present, the preferred R 5 substituent is O, while when γ is absent, the preferred R 5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.